$9.17 +0.28 (%) Compugen Ltd - NASDAQ

Sep. 18, 2014 | 04:00 PM

Partner Headlines

  1. Benzinga's Top #PreMarket Losers

    Benzinga | Jul. 8, 2014 | 08:09AM EST
  2. Benzinga's Top Initiations

    Benzinga | Jun. 18, 2014 | 09:16AM EST
  3. Morning Market Movers

    Benzinga | Jun. 16, 2014 | 09:40AM EST
  4. US Stock Futures Decline Ahead Of Economic Data

    Benzinga | Jun. 16, 2014 | 07:32AM EST
  5. Compugen Reports Positive Experimental Results for Novel Checkpoint Candidate CGEN-15052

    Benzinga | Jun. 16, 2014 | 07:05AM EST
  6. Morning Market Movers

    Benzinga | Mar. 19, 2014 | 09:36AM EST
  7. Benzinga's Top #PreMarket Gainers

    Benzinga | Mar. 19, 2014 | 08:07AM EST
  8. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr

    Benzinga | Feb. 28, 2014 | 10:40AM EST
  9. Compugen Ltd. Prices 6M Share Public Offering at $10.50 per Share

    Benzinga | Feb. 28, 2014 | 09:17AM EST
  10. Benzinga's Top #PreMarket Losers

    Benzinga | Feb. 28, 2014 | 08:15AM EST
  11. Compugen to Significantly Expand Immuno-Oncology Activitiesin 2014

    Benzinga | Jan. 7, 2014 | 09:28AM EST
  12. Compugen, Bayer sign accord

    IBD | Aug. 5, 2013 | 18:43PM EST
  13. Market Wrap For Monday, August 5: Stocks Close Mixed; Nasdaq Rises, Dow And S&P Fall Modestly

    Benzinga | Aug. 5, 2013 | 16:38PM EST
  14. Morning Market Movers

    Benzinga | Aug. 5, 2013 | 10:01AM EST
  15. Compugen Shares Rocket Higher as Co. Announces Collaboration, License Deal with Bayer for Antibody-Based Cancer Immunotherapies

    Benzinga | Aug. 5, 2013 | 09:21AM EST
  16. Compugen Announces Discovery of Two Novel Immune Checkpoint Targets for Cancer Immunotherapy

    Benzinga | Oct. 31, 2012 | 02:24AM EST
  17. Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance

    Benzinga | Sep. 10, 2012 | 01:05AM EST
  18. Towers Watson &, Ubiquiti Networks Among Stocks hitting 52-Week Lows Tuesday

    FoxBusiness | Aug. 14, 2012 | 06:31AM EST
  19. Compugen Says Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy

    Benzinga | Feb. 1, 2012 | 23:42PM EST
Trading Center